Modality
ADC
MOA
GLP-1ag
Target
B7-H3
Pathway
Hedgehog
PsA
Development Pipeline
Preclinical
~Dec 2011
→ ~Mar 2013
Phase 1
~Jun 2013
→ ~Sep 2014
Phase 2
~Dec 2014
→ ~Mar 2016
Phase 3
~Jun 2016
→ ~Sep 2017
NDA/BLA
Dec 2017
→ Mar 2029
NDA/BLACurrent
NCT03181186
1,022 pts·PsA
2017-12→2029-03·Terminated
NCT03633712
367 pts·PsA
2023-05→2025-07·Terminated
1,389 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-07-049mo agoPh3 Readout· PsA
2029-03-122.9y awayPh3 Readout· PsA
Trial Timeline
Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2
NDA/BLA
Termina…
NDA/BLA
Termina…
Catalysts
Ph3 Readout
2025-07-04 · 9mo ago
PsA
Ph3 Readout
2029-03-12 · 2.9y away
PsA
Terminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03181186 | NDA/BLA | PsA | Terminated | 1022 | EASI-75 |
| NCT03633712 | NDA/BLA | PsA | Terminated | 367 | EASI-75 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-8662 | Pfizer | NDA/BLA | CD19 | |
| LLY-4358 | Eli Lilly | Phase 3 | B7-H3 | |
| Ceviglumide | Roche | NDA/BLA | B7-H3 | |
| SNY-9600 | Sanofi | NDA/BLA | B7-H3 | |
| SNY-8628 | Sanofi | NDA/BLA | B7-H3 | |
| SNY-9073 | Sanofi | Phase 2 | B7-H3 | |
| NVO-7840 | Novo Nordisk | Phase 2/3 | B7-H3 | |
| NVO-7872 | Novo Nordisk | NDA/BLA | B7-H3 | |
| DSN-5254 | Daiichi Sankyo | Phase 1 | B7-H3 | |
| Datozumab | Regeneron | Phase 1 | B7-H3 |